EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer Therapeutics

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|3|149-157

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.3, 2005-05, pp. : 149-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging strategies for EphA2 receptor targeting for cancer therapeutics

By Tandon Manish   Vemula Sai Vikram   Mittal Suresh K  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 31-51

Informa Healthcare

Access to resources Recommend Favorite

EphA2 as a target for ovarian cancer therapy

By Landen Charles N   Kinch Michael S   Sood Anil K  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1179-1187

Informa Healthcare

Access to resources Recommend Favorite

The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?

By  

Current Medicinal Chemistry, Vol. 23, Iss. 42, 2016-12 ,pp. : 4718-4734

Bentham Science Publishers

Access to resources Recommend Favorite

Rationale for Ras and Raf-kinase as a Target for Cancer Therapeutics

By  

Current Pharmaceutical Design, Vol. 8, Iss. 25, 2002-11 ,pp. : 2231-2242

Bentham Science Publishers

Access to resources Recommend Favorite

Role of the Non-Receptor Tyrosine Kinase Fes in Cancer

By  

Current Medicinal Chemistry, Vol. 18, Iss. 19, 2011-06 ,pp. : 2913-2920

Bentham Science Publishers

Access to resources Recommend Favorite